Salute e Benessere
Nucleic Acid Aptamers Market to Reach USD 1.2 Billion by 2034: Unique Applications in Drug Delivery & Personalized Medicine Driving Growth | TMR
Since their discovery in the 1990s, several attempts have been made to utilize aptamers as clinical agents for diseases such as AIDS and macular degeneration. It is important to note that the first aptamer-based therapeutic to receive U.S. FDA approval was Macugen (Pegaptanib), that acts as a selective antagonist of vascular endothelial growth factor (VEGF) and is indicated for the treatment of patients suffering from neovascular age-related macular degeneration.
With the surging prevalence of chronic disorders such as cancer, diabetes and cardiovascular conditions, the demand for highly efficient diagnostic and therapeutic strategies is rising. In this context, in 2022, global cancer statistics suggest that nearly 20 million new cases of cancer were reported while the cancer-related mortality toll stood at 9.7 million.
Aptamers are more effective than the conventional approaches used for cancer therapy. The development of aptamers and potential conjugates has made it simple and extremely efficient to distribute medications in a targeted and selective manner.
Recent advancements in SELEX (Systematic Evolution of Ligands through Exponential Enrichment) methods have enabled the screening and filtering of aptamer probes with extremely high specificity to bind to targets, from a library of 10 to 10 single-stranded RNA or DNA molecules.
The global market for nucleic acid aptamers is characterized by the presence of a large number of players. This renders the landscape highly fragmented and competitive. Market players are leveraging the potential of collaborations to introduce cutting-edge product lines.
Besides collaborations, players are vying for the top space with regards to obtaining licenses and certifications. Seeking approvals from regulatory authorities provides them with an opportunity to expand their product base and reach a wider target audience.
, a global registered at Wilmington, Delaware , United States , provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
:
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
+1-518-618-1030
: 866-552-3453
Logo: https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/nucleic-acid-aptamers-market-to-reach-usd-1-2-billion-by-2034-unique-applications-in-drug-delivery--personalized-medicine-driving-growth--tmr-302208443.html